title: Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Ayumi
authors: A
authors: Numata
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Ryoko
authors: R
authors: Kajiyama
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Megumi
authors: M
authors: Itabashi
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Yoshimi
authors: Y
authors: Ishii
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Wataru
authors: W
authors: Yamamoto
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Kenji
authors: K
authors: Motohashi
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Kenji
authors: K
authors: Matsumoto
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Maki
authors: M
authors: Hagihara
authors: b Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
authors: Yoshiaki
authors: Y
authors: Ishigatsubo
authors: a Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
authors: Shin
authors: S
authors: Fujisawa
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002890:Chromosomes, Human, Pair 20; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate